EUCTR2006-004055-38-DE
Active, not recruiting
Not Applicable
A Phase II Clinical Study to Compare the Efficacy and Safety of Three Doses of Topical Glyceryl Trinitrate (GTN) to Placebo in Subjects with Mild and/or Moderate Erectile Dysfunction (ED)
Futura Medical Developments (FMD)0 sites272 target enrollmentJanuary 12, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Mild and/or moderate erectile dysfunction (ED)
- Sponsor
- Futura Medical Developments (FMD)
- Enrollment
- 272
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1\.Aged between 18 and 65 years of age.
- •2\.Males with mild and/or moderate ED for more than 6 months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
- •3\.IIEF\-EF score in the range of 11 to 25 inclusive, denoting mild and/or moderate ED at screening.
- •4\.The subject must make at least four attempts at sexual intercourse (according to the question in the screening phase diary: Was sexual activity initiated with the intention of intercourse?”) on four separate days during the 4 weeks of the treatment\-free run\-in period.
- •5\.50% or more of the attempts during the 4 week run\-in period must be unsuccessful, according to the following questions from the screening phase diary \[at least one question should be answered No]: Were you able to achieve at least some erection (some enlargement of the penis)?”, Were you able to insert your penis into your partner’s vagina?” and Did your erection last long enough for you to have successful intercourse?.
- •6\.Stable monogamous heterosexual relationship for more than 6 months prior to screening.
- •7\.Reproduction and Contraception (at least one of the following criteria must apply):
- •a)Sterile male subjects documented by bilateral vasectomy, bilateral orchiectomy, or azoospermia prior to the subject’s entry into the study, OR
- •b)Female partners of study subjects that are of child bearing potential that are practicing a satisfactory method of contraception for at least 3 months prior to screening:
Exclusion Criteria
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •Previous or Current Medical Conditions
- •1\.Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study.
- •2\.Presence of penile anatomical abnormalities (e.g., phimosis, penile fibrosis or Peyronie’s disease) that, in the opinion of the Investigator, would significantly impair sexual performance.
- •3\.Primary hypoactive sexual desire.
- •4\.Spinal cord injury.
- •5\.History of any pelvic surgery (prostatectomy, colon surgery).
- •6\.A history of priapism.
- •7\.Clinically significant chronic haematological disease which may lead to priapism such as sickle cell anaemia, multiple myeloma or leukaemia.
- •8\.Any underlying cardiovascular condition including unstable angina pectoris that would preclude sexual activity.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to compare the effectiveness of Lotion and Calendula Cream versus Chamomile Cream in an attempt to prevent Skin Reactions in patients with Breast CancerBreast neoplasmsegmental mastectomyradio dermatitisC04.588.180E04.466.701C17.800.174.826RBR-877t2wHospital de Amor de Barretos
Completed
Phase 2
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
Completed
Phase 2
enalidomide and 5azacitidine treatment versus 5azacitidine alone in patients with the blood cancers myelodysplastic syndrome or acute myeloid leukaemiaMyelodysplastic syndromes (MDS)Low marrow blast count acute myeloid leukaemia (AML)Blood - Haematological diseasesCancer - Leukaemia - Acute leukaemiaACTRN12610000271000Australasian Leukaemia and Lymphoma Group160
Active, not recruiting
Phase 1
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)Huntington's diseaseMedDRA version: 18.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-005112-42-FRINSERM50
Completed
Phase 2
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (HD)Huntington's Diseaseneurodegenerative movement disorder1002929910028037NL-OMON43815The French National Institute of Health and Medical Research (Inserm)50